Gary W. Pace Purchases 350,115 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) Stock

Cardiff Oncology, Inc. (NASDAQ:CRDF) Director Gary W. Pace purchased 350,115 shares of the company’s stock in a transaction on Wednesday, December 11th. The stock was bought at an average price of $2.60 per share, for a total transaction of $910,299.00. Following the completion of the purchase, the director now directly owns 1,047,876 shares of the company’s stock, valued at $2,724,477.60. The trade was a 50.18 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Cardiff Oncology Stock Performance

NASDAQ CRDF opened at $3.92 on Friday. The firm’s fifty day moving average is $2.89 and its two-hundred day moving average is $2.61. Cardiff Oncology, Inc. has a one year low of $1.27 and a one year high of $6.42. The firm has a market cap of $200.43 million, a PE ratio of -4.17 and a beta of 1.89.

Wall Street Analyst Weigh In

CRDF has been the topic of a number of recent analyst reports. Craig Hallum began coverage on shares of Cardiff Oncology in a research report on Friday, September 6th. They issued a “buy” rating and a $8.00 target price on the stock. Piper Sandler upped their target price on Cardiff Oncology from $7.00 to $10.00 and gave the company an “overweight” rating in a research report on Friday. Finally, HC Wainwright cut their price target on Cardiff Oncology from $14.00 to $13.00 and set a “buy” rating on the stock in a research report on Friday, November 8th.

Hedge Funds Weigh In On Cardiff Oncology

Several institutional investors have recently added to or reduced their stakes in the stock. Point72 DIFC Ltd acquired a new stake in Cardiff Oncology during the 2nd quarter worth approximately $27,000. Ground Swell Capital LLC acquired a new stake in shares of Cardiff Oncology during the second quarter worth $38,000. Dimensional Fund Advisors LP lifted its holdings in shares of Cardiff Oncology by 34.4% during the second quarter. Dimensional Fund Advisors LP now owns 19,098 shares of the company’s stock worth $42,000 after purchasing an additional 4,892 shares during the period. SG Americas Securities LLC acquired a new position in Cardiff Oncology in the 3rd quarter valued at $64,000. Finally, Invst LLC purchased a new position in Cardiff Oncology during the 2nd quarter worth $74,000. Institutional investors and hedge funds own 16.29% of the company’s stock.

About Cardiff Oncology

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.